The Effect of Angelica gigas Nakai Extract and Bacillus Polyfermenticus KJS-2 on Atopic Dermatitis induced by DNCB in mice

Article information

J Korean Med. 2017;38(3):30-42

Publication date (electronic) : 2017 September 30

doi : https://doi.org/10.13048/jkm.17023

Deok-Hyun Ryu ¹, Sa-Rang Oh ², Tae-Sung Jung ², Deok-Seon Ryu ³^,

¹Dept. of Oriental Medical Ophthalmology & Otolaryngology & Dermatology, College of Oriental Medicine, Dae-jeon University

²Wellbeingtainment Co., Ltd

³Dept. of Biomedical Laboratory Science, Soonchunhyang University

Correspondence to：류덕선(Deok-Seon Ryu) (31538) 충남 아산시 신창면 순천향로 22 임상병리학과(의료과학관 1114호) Tel：+82-41-530-3093, Fax：+82-41-530-3085, E-mail : duckssun@naver.com

Received 2017 July 18; Revised 2017 August 9; Accepted 2017 August 9.

Abstract

Objectives

The purpose of this study was to investigate the effects of Angelica gigas Nakai extract(AGNE) and Bacillus polyfermenticus KJS-2 (BP2) on atopic dermatitis (AD) induced by 2, 4-dinitrochlorobenzene (DNCB) in mice.

Methods

In the experiment, we divided mice into four groups: a control group, a DNCB group, an AGNE group, and an AGNE+BP2 group. Then we examined the changes in scratching frequency, clinical aspects on dorsum skin, immunoglobulin (IgE), cytokines (TNF-α, IL-6) and expression of COX-2.

Resutls

From the experiment, the scratching frequency was significantly dropped in AGNE group and AGNE+BP2 group. Clinical observations of dorsum skin, there were a severe keratotic lesion and drop of dead skin cell in DNCB group, but symptoms of AD were decreased 39.6% in AGNE group and 49.6% in AGNE+BP2 group during 3 weeks. IgE, TNF-α and IL-6 were decreased significantly in both AGNE and AGNE+BP2 group. Expression of COX-2 was also decreased significantly in both groups.

Conclusions

In conclusion, these data suggest that AGNE can decrease symptoms of AD and BP2 makes AGNE more effective. So AGNE can be useful herbal therapy for AD.

Keywords: Angelica gigas Nakai extract (AGNE); Bacillus polyfermenticus KJS-2 (BP2); 2,4-dinitrochlorobenzene (DNCB); Atopic dermatitis (AD)

Fig. 1

Representative high-performance liquid chromatography profile (A) Decursin and decursinol angelate of standard materials (B) AGNE sample.

Fig. 2

The effect of AGNE and AGNE+BP2 on scratching behavior induced by compound 48/80 in ICR mice. AGNE(20 mg/kg), AGNE(20 mg/kg)+BP2(10⁷ CFU) administered orally on the scratching behavior induced by compound 48/80 (50 μg/mouse, s.c.) in mice. AGNE and AGNE+BP2 significantly inhibited the compound 48/80-induced scratching behavior than DNCB group. Each datum represents the means ± S.E.M. of three independent experiments. (*p<0.05 vs. normal group, #p<0.05 vs. compound 48/80-treated group).

Fig. 3

The effect of AGNE and AGNE+BP2 on the DNCB-induced atopic dermatitis. The BALB/c mice (n=6) were sensitized with 150 μL of 0.5% DNCB in acetone–olive oil(3:1) or vehicle applied to the dorsal skin twice each week for a total period of 3 weeks. After 2 weeks, AGNE(20 mg/kg) and AGNE(20 mg/kg)+BP2(10⁷ CFU) was orally administered 1 week prior to the end of the experiment. (A) Comparison of skin manifestation in all groups for 3 weeks (B) SCORAD index of all groups in 0week and 2 weeks. (*p<0.05 vs. normal group, #p<0.05 vs. compound 48/80-treated group).

Fig. 4

The effect of AGNE and AGNE+BP2 on the DNCB-induced IgE level in serum from mice. Blood samples were collected and then the levels of serum IgE in the indicated groups were measured using ELISA method. AGNE and AGNE+BP2 significantly inhibited the DNCB-induced IgE level in serum. Each datum represents the means ±± S.E.M. of three independent experiments(^*p<0.05 vs. normal group, ^#p<0.05 vs. DNCB-treated group, ^$p<0.05 vs. DNCB+AGNE 20 mg/kg-treated group).

Fig. 5

The effect of AGNE and AGNE+BP2 on the DNCB-induced (A) TNF-α and (B) IL-6 levels in serum from mice. Blood samples were collected and then the levels of serum TNF-α and IL-6 in the indicated groups were measured using ELISA method. AGNE+BP2 significantly inhibited the DNCB-induced TNF-α and IL-6 level in serum. Each datum represents the means ± S.E.M. of three independent experiments (^*p<0.05 vs. normal group, ^#p<0.05 vs. DNCB-treated group).

Fig. 6

The effect of AGNE and AGNE+BP2 on the DNCB-induced COX-2 levels in tissue from mice. Tissue samples were collected and then the levels of tissue COX-2 protein in the indicated groups were measured using Western blotting method. AGNE+BP2 significantly inhibited the DNCB-induced COX-2 level in tissue. Each datum represents the means ± S.E.M. of three independent experiments (^*p<0.05 vs. normal group, ^#p<0.05 vs. DNCB-treated group).

Table 1

Intensity Criteria of SCORAD Index

Table 2

Contents of Decursin, Decursinol Angelate, and Polysaccharides from AGNE

Table 3

Contents of a Simple Sugar and Amino Sugar from AGNE

References

1. Bieber T. Atopic dermatitis. N Engl J Med 2008;:1483–94.

2. Park YM. Advan ces In the Pathophysiology of Atopic Dermatitis. Pediatr Allergy Respir Dis 2006;16(3):189–96.

3. Cha KB, Kim YS, Seol IC. Literatual study on Atopic dermatitis. J Res Institute Korean Med Daejeon Univ 2005;14(2):113–26.

4. Park MC, Kim JM, Hong CH, Hwang CY. A literature study about the comparison of Oriental-Occidental medicine on the Atopic dermatitis. J Korean Med Ophthalmol Otolaryngol Dermatol 2002;15(1):226–52.

5. Gong NM, Jee SY. A Literature Study about comparision of Eastern-Western medicine on the Atopic dermatitis. J Korean Med Ophthalmol Otolaryngol Dermatol 1999;12(1):241–53.

6. Chang IM. Treatise on asian herbal medicines. Seoul National Univ Press Inc 2003;1:176–7.

7. An SH, Kim HH. Lonicera Japonica inhibits atopy dermatitis in NC/Nga mouse through regulation of INOS by NF-kB suppression. Korean J Orient Physiol Pathol 2010;24(2):278–83.

8. Lee SI. Phytology Seoul: Suseowon; 1981. p. 101–2.

9. Ahn KS, Sim WS, Kim HM, Han SB, Kim IH. Immunostimulating components from the root of Angelica gigas Nakai. Korean J Pharmacogn 1996;27:254–61.

10. Ahn KS, Sim WS, Kim IH. Decursin a cytotoxic agent and protein kinase c activator from the root of angelica gigias. Planta Med 1995;62:7–9.

11. Kim CH, Kwon MC, Han JG, Na CS, Kwak HG, Choi GP, et al. Skin-Whitening and UV-Protective Effects of Angelica gigas Nakai Extracts on Ultra High Pressure Extraction Process. Korean J Medicinal Crop Sci 2008;16(4):255–60.

12. Jang SI, Kim HJ, Hwang KM, Pae HO, Yun YG, Chung HT, et al. Anti-Inflammatory Effect of Ethanol Extract of Angelica uchiyamana in Activated Murine RAW 264.7 macrophages. Korean J Orient Med Prescription 2002;10(2):189–97.

13. Kim MY, Kwon OJ, Choo BK, Lee CW, Park EH, Kim HJ. The Effect of Angelicae gigantis radix according to Heat-process on Anti-Oxidant and Anti-Thrombotic. Kor J Herbol 2016;31(3):13–22.

14. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest 2004;113(5):651–7.

15. Park MC, Kim JM, Hong CH, Hwang CY. A literature study about the comparison of Oriental-Occidental medicine on the Atopic dermatitis. The Journal of Oriental Medical Surgery, Ophthalmology & Otolaryngology 2002;15(1):226–52.

16. Kim BS. The effect of Bacillus polyfermenticus KJS-2 and Angelica gigias Nakai ethanol extract on hyperlipidemia Department of Pharmacy Graduate School Kyungsung University; 2015.

17. Kang JS, Jun KD, Kim SW, Jo WS, Kwon JY, Moon KH. Antibacterial activities of B. polyfermenticus SCD against pathogenic bacteria and effects on animals and humans. Yakhak hoeji 2004;48(1):70–74.

18. Kim SA, Oh HK, Kim JY, Hong JW, Cho SI. A review of pharmacological effects of Angelica gigas, Angelica sinensis, Angelica acutiloba and their bioactive compounds. J Korean Orient Med 2011;32(4):1–24.

19. Rho SS. Full-color Dermatology. Seoul: IBC design 2006;499:512–27.

20. Park JM, Chae JW. Effects of Aurantii Immaturus Fructus(AI) on Atopic Dermatitis (AD) Induced by DNCB in Mice. J Pediatr Korean Med 2016;29(1):27–43.

21. Jung JY, Han KH. Common skin disease in Korea Seoul: Emdi world; 2009. p. 37–48.

22. Gong NM, Jee SY. A Literature study about comparison of Eastern-Western medicine on the Atopic dermatitis. J Orient Med Ophthalmol Otolaryngol Dermatol 1999;12(1):241–53.

23. Jo SY. Hwalyousimseo Shanghai: Daedongseokgook; 1933. p. 2–8.

24. Wang BD. Yookgwajoonseung Seoul: Seongbosa; 1982. p. 85–7.

25. Jo HC. Sungjechonglok Shinmoonnong 1978;:1439–40.

26. Jang SI, Kim HJ, Hwang KM, Pae HO, Yun YG, Chung HT, et al. Anti-Inflammatory Effect of Ethanol Extract of Angelica uchiyamana in Activated Murin RAW 264,7 macrophages. The Korean Journal of oriental medical prescription 2002;10(2):189–97.

27. Gibson GR, Robertfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995;125:1401–12.

28. Jo EH, Kim TK, Hong SJ, Jung DY, Hwang SY, Ahn SH. The Case Study of Lactobacillus mixture culture fluid on Atopic dermatitis. J Korean Med 2015;36(3):135–43.

29. Kim KM, Kim MJ, Kim DH, Park YS, Kang JS. Characterization of Bacillus polyfermenticus KJS-2 as a probiotic. J Microbiol Biotechnol 2009;19:1013–8.

30. Kim DH, Kang KR, Kim HY, Yoon SY, Kim CG, Tokutaro Y, et al. Structure determination of macrolactin compounds with antibacterial activites isolated from bacillus polyfermenticus KJS-2. J Life Science 2010;:1792–800.

31. Kim HJ. Relation between atopic dermatitis and residential environment. Master’s thesis Dept. of Housing & Interior Design of Yonsei Uni.; 2005.

32. Yang JM. Genetics of atopic dermatitis. Update in dermatology for a dermatologist 2003;:6–9.

33. Leung DYM. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000;105:860–76.

34. Morren Ma, Przybilla B, Bamelis M, Heykants B, Reynaers A, Degreef H. Atopic dermatitis: triggering factors. J Am Acd Dermatol 1994;31:467–73.

35. van Reijsen FC, Bruijinzeel-Koomen CAFM, Kalthoff FS, Maggi E, Romagnani S, Westland JKT, et al. Skin-derived aeroallergen-specific T-cell clones of Th2 Phenotype in patients with atopic dermatitis. J Allergy Clin Immunol 1992;90:184–93.

36. Leung DYM, Sorter NA. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 2001;44:S1–12.

37. Bernnan FM, Maini RN, Feldmann M. Cytokine expression in chronic inflammatory disease. Br Med Bull 1995;51(2):368–84.

38. Baeuerle PA. The inducible transcription activatior NF-κB Regulation by distinct subunits. Biochim Biophys Acta 1991;1072:63–70.

39. Golden BD, Abramson SB. Selective coclooxygenase-2 inhibitor. Rheumatic Disease Clinics of North America 1999;25:359–78.

40. Walgren CF. Itch and atopic dermatitis: an overview. J Dermatol 1999;26:770–9.

41. Park MC, Choi IH. Analysis on the Dermatosurgical Prescriptions in BangYakHapPyun. J Orient Med Ophthalmol Otolaryngol Dermatol 2003;16(1):42–62.

Article information Continued